Veteran NBA referee Scott Wall was diagnosed with acute myeloid leukemia earlier this year, the National Basketball Referees ...
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...
Researchers have identified a key weakness in acute myeloid leukemia, offering a promising new strategy to delay the ...
Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...
NBA referee Scott Wall was diagnosed with acute myeloid leukemia earlier this year and is in treatment, the National ...
A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...
NBA referee Scott Wall was diagnosed with acute myeloid leukemia earlier this year and is in treatment, the National ...
In the phase 2 portion of the phase 1/2 AUGMENT-101 trial, 12 of 64 patients with relapsed or refractory mutant NPM1 acute ...
In8bio recently announced its financial results for the third quarter of 2024, highlighting significant advancements in its INB-100 program for Acute Myeloid Leukemia (AML). The company reported that ...
Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...
Disclosed on November 13, Neena M Patil, EVP & Chief Legal Officer at Jazz Pharmaceuticals JAZZ -2.13% Get Free Report , ...
Fms-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute myeloid leukemia (AML). FLT3 internal tandem duplication (ITD) plays an important role in shaping the clinical ...